早漏疾患治療の米国市場2021年-2025年

調査会社Technavio社が発行したリサーチレポート(データ管理コード:IRTNTR70381)
◆英語タイトル:Premature Ejaculation Disorder Therapeutics Market in US 2021-2025
◆発行会社/調査会社:Technavio
◆商品コード:IRTNTR70381
◆発行日:2021年3月10日
◆調査対象地域:米国
◆産業分野:医療
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[早漏疾患治療の米国市場2021年-2025年]についてメールでお問い合わせはこちら
テクナビオ社は米国の早漏疾患治療市場規模が、2021年~2025年まで年平10%成長し、348.66百万ドルに達すると予測しています。本調査レポートでは、米国の早漏疾患治療市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、投与経路別分析、医薬品クラス別分析、顧客状況、企業状況、企業分析などをまとめております。
*** レポート概要(サマリー)***

Premature ejaculation disorder therapeutics market in US 2021-2025Technavio has been monitoring the premature ejaculation disorder therapeutics market in US and it is poised to grow by $ 348.66 mn during 2021-2025 progressing at a CAGR of 10% during the forecast period. Our report on premature ejaculation disorder therapeutics market in US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current us market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high efficacy of off-label drugs leading to high usage by end-users, demand for topical drug therapies for premature ejaculation treatment, and growing risk factors causing premature ejaculation. In addition, High efficacy of off-label drugs leading to high usage by end-users is anticipated to boost the growth of the market as well.
The premature ejaculation disorder therapeutics market in US market analysis includes type segment and geographical landscapes.

Technavio’s premature ejaculation disorder therapeutics market in US is segmented as below:
By Type
• Oral
• Topical

By Product
• SSRIs
• PDE5 inhibitors
• Amide anesthetics
• Others

This study identifies the advent of nanotechnology as one of the prime reasons driving the premature ejaculation disorder therapeutics market in US growth during the next few years. Also, increasing research and development and emergence of novel wearable products will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on premature ejaculation disorder therapeutics market in US covers the following areas:
• Premature ejaculation disorder therapeutics market in US sizing
• Premature ejaculation disorder therapeutics market in US forecast
• Premature ejaculation disorder therapeutics market in US industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading premature ejaculation disorder therapeutics market in US vendors that include Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Bayer AG, Eli Lilly and Co., InvaGen Pharmaceuticals Inc., Pfizer Inc., Sandoz AG, Solco Healthcare, and Teva Pharmaceutical Industries Ltd.. Also, the premature ejaculation disorder therapeutics market in US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/premature-ejaculation-disorder-therapeutics-market-in-us-industry-analysis
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

*** レポート目次(コンテンツ)***

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Route of Administration
o Market segments
o Comparison by Route of Administration
o Oral – Market size and forecast 2020-2025
o Topical – Market size and forecast 2020-2025
o Market opportunity by Route of Administration
• Market Segmentation by Drug Class
o Market segments
o Comparison by Drug Class
o SSRIs – Market size and forecast 2020-2025
o PDE5 inhibitors – Market size and forecast 2020-2025
o Amide anesthetics – Market size and forecast 2020-2025
o Others – Market size and forecast 2020-2025
o Market opportunity by Drug Class
• Customer Landscape
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Absorption Pharmaceuticals LLC
o Alembic Pharmaceuticals Inc.
o Amneal Pharmaceuticals Inc.
o Bayer AG
o Eli Lilly and Co.
o InvaGen Pharmaceuticals Inc.
o Pfizer Inc.
o Sandoz AG
o Solco Healthcare
o Teva Pharmaceutical Industries Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 5
• 4: Key Finding 6
• 5: Key Finding 7
• 6: Parent market
• 7: Market characteristics
• 8: Offerings of vendors included in the market definition
• 9: Market segments
• 10: Global – Market size and forecast 2020 – 2025 ($ million)
• 11: Global market: Year-over-year growth 2020 – 2025 (%)
• 12: Five forces analysis 2020 & 2025
• 13: Bargaining power of buyers
• 14: Bargaining power of suppliers
• 15: Threat of new entrants
• 16: Threat of substitutes
• 17: Threat of rivalry
• 18: Market condition – Five forces 2020
• 19: Other1 – Market share 2020-2025 (%)
• 20: Comparison by Other1
• 21: Oral – Market size and forecast 2020-2025 ($ million)
• 22: Oral – Year-over-year growth 2020-2025 (%)
• 23: Topical – Market size and forecast 2020-2025 ($ million)
• 24: Topical – Year-over-year growth 2020-2025 (%)
• 25: Market opportunity by Other1
• 26: Other2 – Market share 2020-2025 (%)
• 27: Comparison by Other2
• 28: SSRIs – Market size and forecast 2020-2025 ($ million)
• 29: SSRIs – Year-over-year growth 2020-2025 (%)
• 30: PDE5 inhibitors – Market size and forecast 2020-2025 ($ million)
• 31: PDE5 inhibitors – Year-over-year growth 2020-2025 (%)
• 32: Amide anesthetics – Market size and forecast 2020-2025 ($ million)
• 33: Amide anesthetics – Year-over-year growth 2020-2025 (%)
• 34: Others – Market size and forecast 2020-2025 ($ million)
• 35: Others – Year-over-year growth 2020-2025 (%)
• 36: Market opportunity by Other2
• 37: Customer landscape
• 38: Impact of drivers and challenges
• 39: Vendor landscape
• 40: Landscape disruption
• 41: Industry risks
• 42: Vendors covered
• 43: Market positioning of vendors
• 44: Absorption Pharmaceuticals LLC – Overview
• 45: Absorption Pharmaceuticals LLC – Product and service
• 46: Absorption Pharmaceuticals LLC – Key offerings
• 47: Absorption Pharmaceuticals LLC – Key customers
• 48: Absorption Pharmaceuticals LLC – Segment focus
• 49: Alembic Pharmaceuticals Inc. – Overview
• 50: Alembic Pharmaceuticals Inc. – Product and service
• 51: Alembic Pharmaceuticals Inc. – Key offerings
• 52: Alembic Pharmaceuticals Inc. – Key customers
• 53: Alembic Pharmaceuticals Inc. – Segment focus
• 54: Amneal Pharmaceuticals Inc. – Overview
• 55: Amneal Pharmaceuticals Inc. – Business segments
• 56: Amneal Pharmaceuticals Inc. – Key offerings
• 57: Amneal Pharmaceuticals Inc. – Key customers
• 58: Amneal Pharmaceuticals Inc. – Segment focus
• 59: Bayer AG – Overview
• 60: Bayer AG – Business segments
• 61: Bayer AG – Key offerings
• 62: Bayer AG – Key customers
• 63: Bayer AG – Segment focus
• 64: Eli Lilly and Co. – Overview
• 65: Eli Lilly and Co. – Business segments
• 66: Eli Lilly and Co. – Key offerings
• 67: Eli Lilly and Co. – Key customers
• 68: Eli Lilly and Co. – Segment focus
• 69: InvaGen Pharmaceuticals Inc. – Overview
• 70: InvaGen Pharmaceuticals Inc. – Product and service
• 71: InvaGen Pharmaceuticals Inc. – Key offerings
• 72: InvaGen Pharmaceuticals Inc. – Key customers
• 73: InvaGen Pharmaceuticals Inc. – Segment focus
• 74: Pfizer Inc. – Overview
• 75: Pfizer Inc. – Business segments
• 76: Pfizer Inc. – Key offerings
• 77: Pfizer Inc. – Key customers
• 78: Pfizer Inc. – Segment focus
• 79: Sandoz AG – Overview
• 80: Sandoz AG – Product and service
• 81: Sandoz AG – Key offerings
• 82: Sandoz AG – Key customers
• 83: Sandoz AG – Segment focus
• 84: Solco Healthcare – Overview
• 85: Solco Healthcare – Product and service
• 86: Solco Healthcare – Key offerings
• 87: Solco Healthcare – Key customers
• 88: Solco Healthcare – Segment focus
• 89: Teva Pharmaceutical Industries Ltd. – Overview
• 90: Teva Pharmaceutical Industries Ltd. – Business segments
• 91: Teva Pharmaceutical Industries Ltd. – Key offerings
• 92: Teva Pharmaceutical Industries Ltd. – Key customers
• 93: Teva Pharmaceutical Industries Ltd. – Segment focus
• 94: Currency conversion rates for US$
• 95: Research Methodology
• 96: Validation techniques employed for market sizing
• 97: Information sources
• 98: List of abbreviations



*** 掲載企業 ***

Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Bayer AG, Eli Lilly and Co., InvaGen Pharmaceuticals Inc., Pfizer Inc., Sandoz AG, Solco Healthcare, Teva Pharmaceutical Industries Ltd.

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(IRTNTR70381 )"早漏疾患治療の米国市場2021年-2025年" (英文:Premature Ejaculation Disorder Therapeutics Market in US 2021-2025)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。